Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$37.62M+16.9%$32.18M0.0%$32.17M+16.0%$27.72M-54.8%$61.29M+204%
$8.49M+27.8%$6.65M+8.1%$6.15M+4.2%$5.9M+7.7%$5.48M+54.8%
$46.11M+18.8%$38.82M+1.3%$38.32M+14.0%$33.62M-49.6%$66.77M+182%
$46.11M+18.8%$38.82M+1.3%$38.32M+14.0%$33.62M-49.6%$66.77M+182%
-$46.11M-18.8%-$38.82M-1.3%-$38.32M-14.0%-$33.62M+49.6%-$66.77M-182%
$2.79M-14.9%$3.28M-1.8%$3.34M+50.1%$2.22M-6.8%$2.39M-22.4%
-$43.32M-21.9%-$35.54M-1.6%-$34.98M-11.4%-$31.4M+51.2%-$64.39M-212%
-$0.96-23.1%-$0.78+6.0%-$0.83+7.8%-$0.90+52.6%-$1.90-211%
-$0.96-23.1%-$0.78+6.0%-$0.83+7.8%-$0.90+52.6%-$1.90-211%
45.1M+17.2%38.5M-8.2%41.9M+19.7%35M+3.3%33.9M+7.7%
45.1M+17.2%38.5M-8.2%41.9M+19.7%35M+3.3%33.9M+7.7%
-$43.6M-22.0%-$35.74M-2.8%-$34.75M-10.7%-$31.4M+51.1%-$64.19M-208%
$2.79M-14.9%$3.28M-1.8%$3.34M+50.1%$2.22M-6.8%$2.39M-22.4%
-$284K$226K+22,700%-$1K-101%$194K+468%
-$284K$226K+22,700%-$1K-101%$194K+468%
-$46.11M-18.8%-$38.82M-1.3%-$38.32M-14.0%-$33.62M+49.6%-$66.77M-182%
-$46.67M-17.9%-$39.58M-1.3%-$39.07M-13.7%-$34.38M+49.1%-$67.53M
-$46.67M-17.9%-$39.58M-1.3%-$39.07M-13.7%-$34.38M+49.1%-$67.53M
-$46.11M-18.8%-$38.82M-1.3%-$38.32M-14.0%-$33.62M+49.6%-$66.77M-182%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is ArriVent BioPharma, Inc. profitable?
ArriVent BioPharma, Inc. is not currently profitable: it reported a net loss of $145.2M over the trailing twelve months.
What is ArriVent BioPharma, Inc.'s earnings per share?
ArriVent BioPharma, Inc.'s diluted EPS over the trailing twelve months is $-3.47.
Where does ArriVent BioPharma, Inc.'s income statement data come from?
Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.